Titre :
  • Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also
Auteur : Bartlett, John M S ; Poole, Christopher ; Shepherd, Lois ; Cardoso, Fatima ; Jensen, Maj Britt ; Caldas, Carlos ; Twelves, Chris C. ; Rea, Daniel William D.W. ; Ejlertsen, Bent ; Leo, Angelo ; Pritchard, Kathleen ; McConkey, Christopher C.C. ; Munro, Alison ; Desmedt, Christine ; Dunn, Janet J.A. ; Larsimont, Denis ; O'Malley, Frances Philomena F.P. ; Cameron, David D.A. ; Earl, Helena
Informations sur la publication : Journal of clinical oncology, 33, 15, (page 1680-1687)
Statut de publication : Publié, 2015-05
Sujet CREF : Cancérologie
Mots-clés MeSH : Anthracyclines -- therapeutic use
Antigens, Neoplasm -- genetics
Antineoplastic Agents -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Biomarkers, Tumor
Centromere -- chemistry
Chromosomes, Human, Pair 17 -- genetics
Clinical Trials, Phase III as Topic
Cyclophosphamide -- therapeutic use
DNA Topoisomerases, Type II -- genetics
DNA-Binding Proteins -- genetics
Disease-Free Survival
Fluorescent Dyes -- chemistry
Fluorouracil -- therapeutic use
Genetic Markers
Humans
In Situ Hybridization, Fluorescence
Methotrexate -- therapeutic use
Neoplasm Recurrence, Local
Neoplasms -- drug therapy -- genetics
Prognosis
Proportional Hazards Models
Treatment Outcome
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0732-183X 
info:doi/10.1200/JCO.2013.54.7869
info:pii/JCO.2013.54.7869
info:pmid/25897160